Charles Silberstein's most recent trade in Applied Therapeutics Inc was a trade of 47,900 Common Stock done . Disclosure was reported to the exchange on Jan. 7, 2022.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Applied Therapeutics Inc | Charles Silberstein | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2022 | 47,900 | 183,603 (0%) | 0% | 0 | Common Stock | |
| Applied Therapeutics Inc | Charles Silberstein | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2022 | 32,000 | 32,000 | - | - | Employee Stock Option (Right to Buy) | |
| Applied Therapeutics Inc | Charles Silberstein | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Dec 2021 | 47,900 | 135,703 (0%) | 0% | 0 | Common Stock | |
| Applied Therapeutics Inc | Charles Silberstein | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Dec 2021 | 32,000 | 32,000 | - | - | Employee Stock Option (Right to Buy) | |
| Applied Therapeutics Inc | Charles Silberstein | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 21.42 per share. | 08 Jun 2021 | 5,047 | 87,803 (0%) | 0% | 21.4 | 108,107 | Common Stock |
| Applied Therapeutics Inc | Charles Silberstein | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Dec 2020 | 92,850 | 92,850 | - | - | Stock Option (Right to Buy) |